• 'Unacceptable corporate greed': Senator slams Moderna for proposed vaccine cost

    Sen. Bernie Sanders sent a letter to Moderna's CEO urging the company to reconsider its price per dose in light of the federal government's role in developing the vaccine.
  • FDA takes wary approach on trials with cutting-edge drugs: WSJ

    The FDA is increasingly hesitant on allowing drugmakers to test their cell and gene therapy candidates in human trials, The Wall Street Journal reported Jan. 10. 
  • Nasal COVID-19 vaccines: 7 things to know

    With the COVID-19 public health emergency approaching an end date and some vaccine-makers prepping for their shots to plunge into the U.S. market, many anticipate nasal COVID-19 vaccines to join the fray. 
  • Navitus Health Solutions, Banjo Health partner on prior authorizations

    Navitus Health Solutions and Banjo Health are partnering to modernize and streamline prior authorization workflows for health plan clients, members and prescribers.
  • AHA 'disappointed' as 340B case returns to HHS

    The American Hospital Association said it's "disappointed" after a district court ruled to return a 340B funding case back to HHS to determine the appropriate remedy for the delayed payments, according to a Jan. 10 statement. 
  • Moderna floats $110-$130 COVID-19 shot price

    Moderna is ruminating about pricing its COVID-19 vaccine to cost between $110 and $130 once the federal government stops paying for it, The Wall Street Journal reported Jan. 9. 
  • Drug formulary exclusions rise in 2023 

    Caremark, Express Scripts and OptumRx — the three largest pharmacy benefit managers in the U.S. — increased the number of drugs excluded from their formularies in 2023, according to a Jan. 10 blog post from the Drug Channels Institute.
  • Moderna expects vaccine sales to plummet 72.8% in 2023 + 4 updates

    Moderna's revenue from its COVID-19 vaccine is expected to drop 72.8 percent, from $18.4 billion to a minimum of $5 billion, from 2022 to 2023's annual sales, the company said Jan. 9. 
  • SSM Health's response to current drug shortages

    With multiple retail pharmacies short on medicine cabinet staples amid a rise in flu and respiratory syncytial virus cases, St. Louis-based SSM Health's pharmacy leader told the Wisconsin State Journal some drug shortage tips. 
  • Pharmacist compounds medicines in wake of Tylenol shortages

    An Iowa pharmacy is relying on "old school" methods to provide liquid forms of common medications to children, ABC affiliate KCCI reported Jan. 8.
  • XBB.1.5 likely resistant to Evusheld, FDA says

    Evusheld, the only COVID-19 preexposure prophylaxis treatment with emergency use authorization, may not be effective against subvariant XBB.1.5, which makes up nearly 3 in 10 cases, the FDA said Jan. 6. 
  • FDA approves 3rd Alzheimer's drug

    The FDA handed Biogen and Eisai's new Alzheimer's drug accelerated approval Jan. 6. 
  • Pfizer gets FDA priority review for pneumonia vaccine

    The FDA accepted Pfizer for a priority review of a supplemental Biologics License Application for its pneumococcal conjugate vaccine for children.
  • Moderna, oncology drug company partner to broaden mRNA use

    Moderna and CytomX Therapeutics, a cancer drug company, will collaborate to develop investigational mRNA-based therapies, the companies said Jan. 5. 
  • 1st pediatric RSV drug could be approved before next viral season

    The FDA accepted AstraZeneca and Sanofi's application for their pediatric respiratory syncytial virus drug Jan. 5, and if approved, it would be the first single-dose preventive option for a virus that infects nearly all children before the age of 2. 
  • Paxlovid use ebbs amid lack of funds, unclear rebound risk

    Millions of Paxlovid packets haven't been used, which could be tied to COVID-19 rebound risks, less federal funds and diminishing public concern about the pandemic, according to an article published Jan. 3 in Nature. 
  • Walgreens, CVS plan to dispense abortion pills

    After the FDA said it would allow some retail pharmacies to dispense prescribed abortion pills, Walgreens and CVS told Becker's they plan to distribute the drug mifepristone. 
  • Pediatric pain medication shortage delaying care: 5 updates

    As retail pharmacy chains ration sales of children's pain medications amid a national shortage, some physicians are delaying operations as families scramble for medicine cabinet staples. 
  • 10 systems seeking pharmacy leaders

    The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week.
  • 12 blood pressure drugs back-ordered, partly because of carcinogen

    Three drugmakers each have four blood pressure drugs in short supply after some were recalled in 2022 because of the presence of nitrosamine, which the FDA has labeled as a "probable human carcinogen."

Featured Whitepapers

Featured Webinars